Compare · AYTU vs AZN
AYTU vs AZN
Side-by-side comparison of Aytu BioPharma Inc. (AYTU) and AstraZeneca PLC (AZN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AYTU and AZN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $257.84B, about 10444.6x AYTU ($24.7M).
- Over the past year, AYTU is down 2.5% and AZN is down 11.7% - AYTU leads by 9.2 points.
- AZN has been more active in the news (15 items in the past 4 weeks vs 1 for AYTU).
- AZN has more recent analyst coverage (25 ratings vs 2 for AYTU).
- Company
- Aytu BioPharma Inc.
- AstraZeneca PLC
- Price
- $2.34-1.27%
- $166.30-1.98%
- Market cap
- $24.7M
- $257.84B
- 1M return
- +11.69%
- -3.62%
- 1Y return
- -2.50%
- -11.68%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 1
- 15
- Recent ratings
- 2
- 25
Aytu BioPharma Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AYTU
- Amendment: SEC Form SCHEDULE 13G/A filed by Aytu BioPharma Inc.
- Chief Commercial Officer Pyszczymuka Greg was granted 20,000 shares, increasing direct ownership by 55% to 56,102 units (SEC Form 4)
- Chief Executive Officer Disbrow Joshua R. was granted 30,000 shares, increasing direct ownership by 14% to 237,203 units (SEC Form 4)
- Chief Business Officer Disbrow Jarrett was granted 15,000 shares, increasing direct ownership by 24% to 76,568 units (SEC Form 4)
- Chief Financial Officer Selhorn Ryan J was granted 25,000 shares, increasing direct ownership by 50% to 74,743 units (SEC Form 4)
- Director Liu Vivian H was granted 10,000 shares, increasing direct ownership by 50% to 29,825 units (SEC Form 4)
- Director Jain Abhinav was granted 10,000 shares, increasing direct ownership by 51% to 29,500 units (SEC Form 4)
- Director Dockery Carl was granted 10,000 shares, increasing direct ownership by 47% to 31,152 units (SEC Form 4)
- Director Donofrio John Jr. was granted 10,000 shares, increasing direct ownership by 73% to 23,762 units (SEC Form 4)
- Aytu BioPharma Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
Latest AZN
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
- TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO